Latest revision as of 21:21, 12 February 2024
Information about message (contribute ) This message has no documentation.
If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (SGLT2 inhibitor ) Dapagliflozin disposition is not evidently affected by BMI or [[body weight]], therefore the pharmacokinetic findings are expected to be applicable to patients with a higher [[Body mass index|BMI]]. Dapagliflozin resulted in [[dose-dependent]] increases excretions in urinary glucose, up to 47g/d following single-dose administration, which can be expected from its [[mechanism of action]], dapagliflozin.
ダパグリフロジンの体内動態はBMIや体重 に明らかに影響されないため、薬物動態学的知見はBMI の高い患者にも適用できると予想される。ダパグリフロジンの作用機序 から予想されるように、ダパグリフロジンは用量依存的 に尿中グルコース排泄量を増加させ、単回投与で最大47g/dであった。